Axxcess Wealth Management LLC Purchases 9,256 Shares of Abbott Laboratories $ABT

Axxcess Wealth Management LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 7.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 139,998 shares of the healthcare product maker’s stock after purchasing an additional 9,256 shares during the period. Axxcess Wealth Management LLC’s holdings in Abbott Laboratories were worth $18,751,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. IMG Wealth Management Inc. lifted its holdings in Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares during the last quarter. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth about $31,000. Anfield Capital Management LLC grew its stake in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter valued at about $32,000. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Leerink Partners reduced their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Evercore reduced their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Citigroup lowered their price objective on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. BTIG Research reduced their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Finally, Piper Sandler lowered their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Trading Down 0.4%

Shares of ABT opened at $112.27 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The firm has a market cap of $195.22 billion, a price-to-earnings ratio of 30.18, a PEG ratio of 1.79 and a beta of 0.75. The business’s fifty day moving average is $119.12 and its 200-day moving average is $126.18.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period last year, the firm posted $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a $0.63 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.